Pricing & Access· May 26, 2026 · 7 min read
Veppanu (vepdegestrant) coverage guide: the first PROTAC degrader for ER+/HER2− breast cancer
By Ran Chen#PROTAC#Breast Cancer#Companion Diagnostic
Topic
Companion Diagnostic
FDA-approved companion diagnostics, biomarker testing requirements, liquid biopsy, and how diagnostic requirements shape drug access workflows.